Search Result |
Top |
| Entry | Name | Description | Category | Pathway | Gene |
|---|---|---|---|---|---|
| H00013 | Small cell lung cancer | Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of ... | Cancer | hsa05222 Small cell lung cancer |
MYC (amplification) [HSA:4609] [KO:K04377] BCL2 (overexpression) [HSA:596] [KO:K02161] FHIT [HSA:2272] [KO:K01522] TP53 [HSA:7157] [KO:K04451] RB1 [HSA:5925] [KO:K06618] PTEN [HSA:5728] [KO:K01110] PPP2R1B [HSA:5519] [KO:K03456] |
| H00041 | Kaposi sarcoma | Kaposi sarcoma (KS) is an angioproliferative disease classified into classic KS, endemic KS, iatrogenic KS, and HIV-associated KS (HIV-KS), however, they share the same histological traits and are all ... | Cancer; Viral infectious disease | hsa05167 Kaposi sarcoma-associated herpesvirus infection |
BCL2 (overexpression) [HSA:596] [KO:K02161] MYC (overexpression) [HSA:4609] [KO:K04377] FGF3 (overexpression, mutation) [HSA:2248] [KO:K04358] KRAS (overexpression, mutation) [HSA:3845] [KO:K07827] TP53 [HSA:7157] [KO:K04451] |
| H00054 | Nasopharyngeal cancer | Nasopharyngeal carcinoma (NPC) is a rare disease in most parts of the world, with an age-standardised annual incidence of less than 1 per 100000. However, in Southern China, parts of Southeast Asia and ... | Cancer |
(NPCA3) MST1R [HSA:4486] [KO:K05100] RASSF1 (promoter hypermethylation) [HSA:11186] [KO:K09850] CDKN2A (promoter hypermethylation) [HSA:1029] [KO:K06621] BCL2 (overexpression) [HSA:596] [KO:K02161] EDNRB (promoter hypermethylation) [HSA:1910] [KO:K04198] CADM1 (promoter hypermethylation) [HSA:23705] [KO:K06781] CDH1 (decreased expression) [HSA:999] [KO:K05689] |
|
| H01613 | Follicular lymphoma | Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by diffuse lymphoadenopathy, bone marrow involvement ... | Cancer |
IgH-BCL2 (translocation) [HSA:596] [KO:K02161] EZH2 (mutation) [HSA:2146] [KO:K11430] MLL2 (mutation) [HSA:9757 8085] [KO:K14959 K09187] CREBBP (mutation) [HSA:1387] [KO:K04498] MEF2B (mutation) [HSA:4207] [KO:K09261] EP300 (mutation) [HSA:2033] [KO:K04498] |
|
| H02434 | Diffuse large B-cell lymphoma, not otherwise specified | ... (EZH2, EP300), B-cell homing (GNA13, GNAI2), PI3K pathway signalling (PTEN), and apoptotic pathway (BCL2). In contrast, ABC subtype is driven by frequent mutations in the B cell receptor and NFKB pathways ... | Cancer |
EZH2 (mutation) [HSA:2146] [KO:K11430] CREBBP (mutation/deletion) [HSA:1387] [KO:K04498] EP300 (mutation/deletion) [HSA:2033] [KO:K04498] GNA13 (mutation) [HSA:10672] [KO:K04639] GNAI2 (mutation) [HSA:2768] [KO:K04346] TNFRSF14 (mutation) [HSA:8764] [KO:K05152] BCL6 (mutation) [HSA:604] [KO:K15618] MYC (chromosomal translocation) [HSA:4609] [KO:K04377] PTEN (deletion) [HSA:5728] [KO:K01110] BCL2 (chromosomal translocation / mutation) [HSA:596] [KO:K02161] CARD11 (mutation) [HSA:84433] [KO:K07367] CD79A (mutation) [HSA:973] [KO:K06506] CD79B (mutation) [HSA:974] [KO:K06507] TNFAIP3 (mutation/deletion) [HSA:7128] [KO:K11859] MYD88 (mutation) [HSA:4615] [KO:K04729] CDKN2A (deletion) [HSA:1029] [KO:K06621] CDKN2B (deletion) [HSA:1030] [KO:K04685] PRDM1 (mutation/deletion) [HSA:639] [KO:K24501] MLL2 (mutation) [HSA:8085] [KO:K09187] MLL3 (mutation) [HSA:58508] [KO:K09188] B2M (mutation/deletion) [HSA:567] [KO:K08055] CD58 (mutation/deletion) [HSA:965] [KO:K06492] TP53 (mutation) [HSA:7157] [KO:K04451] MEF2B (mutation) [HSA:100271849] [KO:K09261] FOXO1 (mutation) [HSA:2308] [KO:K07201] |
| [ KEGG | DISEASE | DRUG | MEDICUS ] |